Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03

Pfizer announces FDA approves IXIFI, a biosimilar to Remicade

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

  • 04

    Jan

PFE Pfizer
$36.64

0.06 (0.16%)

11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

, LGF.B

Lionsgate

$32.84

2.46 (8.10%)

08:34
01/19/18
01/19
08:34
01/19/18
08:34
Recommendations
Lionsgate, Lionsgate analyst commentary  »

Lionsgate price target…

LGF.A

Lionsgate

$34.50

2.22 (6.88%)

LGF.B

Lionsgate

$32.84

2.46 (8.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

HMNY

Helios and Matheson

$8.14

0.41 (5.30%)

08:32
01/19/18
01/19
08:32
01/19/18
08:32
Hot Stocks
MoviePass announces MoviePass Ventures to co-acquire films »

MoviePass, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$32.75

2.09 (6.82%)

08:32
01/19/18
01/19
08:32
01/19/18
08:32
Recommendations
Ichor Holdings analyst commentary  »

Ichor Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ABMD

Abiomed

$225.89

1.76 (0.79%)

08:31
01/19/18
01/19
08:31
01/19/18
08:31
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

GTXI

GTx

$12.65

0.15 (1.20%)

08:30
01/19/18
01/19
08:30
01/19/18
08:30
Options
Three new option listings on January 19th »

New option listings for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:30
01/19/18
01/19
08:30
01/19/18
08:30
Hot Stocks
Oramed CEO: Oral GLP-1 analog development is rapidly proceeding »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
SF Fed's Williams is being considered for the Vice Chair spot »

SF Fed's Williams is…

08:30
01/19/18
01/19
08:30
01/19/18
08:30
General news
Breaking General news story  »

Atlanta Federal Reserve…

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

08:29
01/19/18
01/19
08:29
01/19/18
08:29
Hot Stocks
AstraZeneca reports Fasenra receives approval in Japan »

AstraZeneca and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

  • 08

    Mar

  • 23

    Apr

SYF

Synchrony

$37.30

-0.76 (-2.00%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Technical Analysis
Technical Take: Synchrony falls after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SM

SM Energy

$25.69

-0.93 (-3.49%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Conference/Events
SM Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

SBNY

Signature Bank

$153.44

5.39 (3.64%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Signature Bank analyst commentary  »

Signature Bank price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$61.84

0.67 (1.10%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Recommendations
Atlassian analyst commentary  »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Hot Stocks
Oramed CEO: 2018 will be an exciting and event driven year »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

, CBG

CBRE Group

$45.19

0.2 (0.44%)

08:26
01/19/18
01/19
08:26
01/19/18
08:26
Conference/Events
Bay Area Council Economic Institute to hold a conference »

11th Annual Forecast…

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

CBG

CBRE Group

$45.19

0.2 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Feb

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Federal Reserve Bank of San Francisco President speaks at conference »

Federal Reserve Bank of…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

, STRA

Strayer

$92.18

-0.64 (-0.69%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Strayer to host special shareholder meeting »

Special shareholder…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

STRA

Strayer

$92.18

-0.64 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

EXEL

Exelixis

$27.86

0.37 (1.35%)

, IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Exelixis and Ipsen co-host a financial community briefing »

Exelixis and Ipsen…

EXEL

Exelixis

$27.86

0.37 (1.35%)

IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

OCUL

Ocular Therapeutix

$5.54

-0.02 (-0.36%)

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Upgrade
Ocular Therapeutix rating change  »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Conference/Events
Federal Reserve Bank of Atlanta President speaks at breakfast meeting »

Federal Reserve Bank of…

IBM

IBM

$169.12

0.47 (0.28%)

08:23
01/19/18
01/19
08:23
01/19/18
08:23
Recommendations
IBM analyst commentary  »

IBM price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

08:22
01/19/18
01/19
08:22
01/19/18
08:22
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.